We have explored *in vitro* and *in vivo* the immunomodulatory activities of simvastatin, an HMG Co-A reductase (HMGR) inhibitor, in the context of inflammatory arthritis.

Methods
=======

Lymphocyte/monocyte populations were purified from peripheral blood (PB) and synovial fluid/tissues (SF/ST) from rheumatoid arthritis (RA) patients or normal controls as appropriate. Fibroblast-like synoviocytes (FLS) were obtained by serial culture from RAST and utilised from passage 3. T cells were mitogen or cytokine (IL-15) activated then fixed in PFA prior to co-culture with macrophages. Collagen-induced arthritis (CIA) developed in male DBA/1 mice on d26 following priming (d0)/ip challenge (d21) with type II collagen in CFA.

Results
=======

*In vitro*, simvastatin significantly suppressed macrophage TNFα release following cell contact with cytokine or mitogen activated T cells whether derived from normal or RAPB or from RA SF. Constitutive release of IL-6 by RAFLS was dose dependently suppressed by simvastatin (*P* \< 0.05). *In vivo*, simvastatin administration (up to 40 mg/kg ip, n = 12/group) from d21 reduced plasma cholesterol by 20% and prevented the development of CIA in a dose dependent manner in comparison with injection of drug vehicle alone (*P* \< 0.01). *Ex vivo* analysis indicated significant suppression of collagen-specific humoral and cellular immune responses. Moreover, administration of simvastatin (40 mg/kg) significantly suppressed established arthritis (n = 20/group) compared with drug vehicle (*P* \< 0.01).

Conclusions
===========

Simvastatin modulated the release of cell-contact induced proinflammatory cytokines *in vitro* from cells of RAPB and synovial origin. Both developing and importantly, established CIA were significantly suppressed by administration of simvastatin *in vivo*. These data demonstrate for the first time the anti-inflammatory, therapeutic potential of HMGR inhibitors in inflammatory arthritis.
